Ian Bezek

Ian Bezek

InvestorPlace Contributor

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Camber Energy Is a Terrible Way to Bet on Higher Oil Prices

By Ian Bezek, InvestorPlace Contributor

Oil and gas companies are red hot right now, but don't get stuck buying third-tier picks such as CEI stock.

Can New Management Turn Warner Brothers Discovery Around?

By Ian Bezek, InvestorPlace Contributor

WBD stock looks dirt cheap in some regards. However, there are real questions about the company's ability to manage changing market conditions.

Sounding Out the Bullish Scenario for Sonos Stock

By Ian Bezek, InvestorPlace Contributor

SONO stock has slumped as traders fear a sales decline in coming quarters. However, the situation isn't as bad as people might expect.

Teladoc Health’s Vital Signs Are Not Getting Better

By Ian Bezek, InvestorPlace Contributor

Teladoc has been caught up in the wave as the tech sector has sunk. But it's getting increasingly hard to dismiss TDOC stock's specific flaws, as well.

Profitability Remains Elusive for ChargePoint Despite Rapid Growth

By Ian Bezek, InvestorPlace Contributor

ChargePoint is growing quickly, but CHPT stock needs investors to wade back into the growth stock pool before it can shine.

How Government Subsidies Impact Enphase Energy Stock

By Ian Bezek, InvestorPlace Contributor

ENPH stock took a hit recently on subsidy issues in the United States, but Europe remains a bright spot.

Sundial Growers: Earnings Were a Positive Surprise

By Ian Bezek, InvestorPlace Contributor

Sundial Growers is in much better position than your average penny stock. Here's why SNDL stock still has a shot even under 50 cents per share.

Cassava Sciences May Be Heading Below $10 Per Share

By Ian Bezek, InvestorPlace Contributor

Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall.

ToughBuilt Industries Stock Could See Another Downward Spiral

By Ian Bezek, InvestorPlace Contributor

In theory, ToughBuilt could be a high-quality business. However, its excessive operating expenses have caused incredible harm to TBLT stock.

Newegg Stock Has Far Too Many Red Flags to Recommend to Anyone

By Ian Bezek, InvestorPlace Contributor

Newegg might be a nostalgic name for some traders. However, NEGG stock is not a good way to play a potential meme stock revival.

Load More